Edesa Biotech, Inc. (EDSA)

NASDAQ: EDSA · IEX Real-Time Price · USD
4.360
-0.090 (-2.02%)
Mar 28, 2024, 10:39 AM EDT - Market open

Company Description

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.

Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.

The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo.

It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.

The company was founded in 2015 and is headquartered in Markham, Canada.

Edesa Biotech, Inc.
Edesa Biotech logo
Country Canada
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Dr. Pardeep Nijhawan FRCPC, M.D.

Contact Details

Address:
100 Spy Court
Markham, A6 L3R 5H6
Ontario, Canada
Phone (905) 475-1234
Website edesabiotech.com

Stock Details

Ticker Symbol EDSA
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001540159
CUSIP Number 27966L108
ISIN Number CA27966L3065
SIC Code 2834

Key Executives

Name Position
Dr. Pardeep Nijhawan FRCPC, M.D. Chief Executive Officer, Company Secretary and Director
Dr. Michael J. Brooks M.B.A., Ph.D. President
Stephen L. Lemieux BA, CA, CPA, MMPA Chief Financial Officer

Latest SEC Filings

Date Type Title
Feb 9, 2024 10-Q Quarterly Report
Feb 9, 2024 8-K Current Report
Jan 29, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 16, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Dec 15, 2023 10-K Annual Report
Dec 15, 2023 8-K Current Report
Oct 26, 2023 8-K Current Report
Oct 23, 2023 8-K Current Report
Oct 12, 2023 8-K Current Report
Oct 11, 2023 8-K Current Report